• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Haoxi Health Technology Limited Announces the Closing of a $12 Million Underwritten Follow-on Public Offering

    9/20/24 4:05:00 PM ET
    $HAO
    Advertising
    Consumer Discretionary
    Get the next $HAO alert in real time by email

    BEIJING, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the "Company" or "HAO"), an online marketing solution provider headquartered in Beijing, China, today announced that it closed its previously announced underwritten follow-on offering of 4,000,000 units (each a "Unit," and collectively, the "Units") at a public offering price of $3.00 per Unit (the "Offering"). Each Unit consists of (i) one share of Class A Ordinary Share, par value $0.0001 per share (the "Class A Ordinary Share") (or one pre-funded warrant to purchase one Class A Ordinary Share (the "Pre-Funded Warrant")), (ii) one Series A warrant to purchase one Class A Ordinary Share (the "Series A Warrant") initially, but five Class A Ordinary Shares on and after the Series B Exercise Date, and (iii) one Series B warrant to purchase four of Class A Ordinary Shares on and after the sixteenth (16th) calendar day (the "Series B Exercise Date") following the closing of the Offering (the "Series B Warrant", together with the Series A Warrant, the "Warrants"). The Units have no stand-alone rights and therefore are not certificated or issued as stand-alone securities. The Class A Ordinary Shares and related Warrants are issued separately in the Offering. The Company received aggregate gross proceeds of $12,000,000 from the Offering, before deducting underwriting discounts and other offering expenses, excluding the exercise of any Warrants.

    The Offering has been conducted on a firm commitment basis. The Company has granted EF Hutton LLC ("EF Hutton"), the underwriter, an option, within 45 days from the closing date, to purchase up to an additional 600,000 Units at the public offering price, less underwriting discounts, to cover the over-allotment.

    EF Hutton is acting as the sole bookrunner for the Offering. Hunter Taubman Fischer & Li LLC is acting as U.S. counsel to the Company, and Pryor Cashman LLP is acting as U.S. counsel to EF Hutton, in connection with the Offering.

    "We are pleased to close this offering and appreciate the continued support and market recognition as we execute our business plan" said Mr. Zhen Fan, Chairman and CEO of HAO. "The proceeds provided by this offering will help facilitate our continued business expansion and technologies investment in healthcare industry."

    The registration statement on Form F-1 (File No. 333-280174) relating to the Offering, as amended, was filed with the U.S. Securities and Exchange Commission (the "SEC"), and was declared effective by the SEC on September 19, 2024. The Offering is being made only by means of a prospectus. Copies of the final prospectus related to the Offering may be obtained, from EF Hutton, Attn: Syndicate Department, 590 Madison Avenue, 39th Floor, New York, NY 10022, or via email at [email protected] or telephone at (212) 404-7002. In addition, a copy of the final prospectus can also be obtained via the SEC's website at www.sec.gov.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Haoxi Health Technology Limited

    Haoxi Health Technology Limited is a Beijing-headquartered online marketing solution provider in China, specializing in serving healthcare industry advertiser clients. The Company's growth is driven by the rise of news feed ads and the rapid development of the healthcare sector. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, WeChat, and Sina Weibo. It is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers. For more information, please visit: http://ir.haoximedia.com.

    Forward-Looking Statement

    This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may", "will", "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the expected trading of its Ordinary Shares on the Nasdaq Capital Market and the closing of the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

    For more information, please contact:

    Underwriter

    EF Hutton LLC

    Ms. Stephanie Hu, Head of Asia, Investment Banking

    Email: [email protected]  

    Investor Relations

    WFS Investor Relations Inc.

    Janice Wang, Managing Partner

    Email: [email protected]

    Phone: +86 13811768599

    +1 628 283 9214



    Primary Logo

    Get the next $HAO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HAO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HAO
    SEC Filings

    See more
    • SEC Form EFFECT filed by Haoxi Health Technology Limited

      EFFECT - Haoxi Health Technology Ltd (0001954594) (Filer)

      6/16/25 12:15:22 AM ET
      $HAO
      Advertising
      Consumer Discretionary
    • Amendment: SEC Form F-3/A filed by Haoxi Health Technology Limited

      F-3/A - Haoxi Health Technology Ltd (0001954594) (Filer)

      6/10/25 4:15:49 PM ET
      $HAO
      Advertising
      Consumer Discretionary
    • SEC Form F-3 filed by Haoxi Health Technology Limited

      F-3 - Haoxi Health Technology Ltd (0001954594) (Filer)

      5/30/25 4:23:21 PM ET
      $HAO
      Advertising
      Consumer Discretionary

    $HAO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Haoxi Health Technology Limited Launches Customized Livestreaming Agency Strategy

      BEIJING, April 21, 2025 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the "Company" or "HAO"), an online marketing solution provider headquartered in Beijing, China, announced that Beijing Haoxi Digital Technology Co., Ltd. ("Haoxi Beijing"), a wholly-owned subsidiary of the Company, has launched its customized livestreaming agency strategy and is progressing partnership discussions on personalized livestreaming agency services with several long-term clients of medical aesthetics, marking a new strategic step in the Company's business development roadmap. Driven by the growing demand for personalized and high-quality services in the healthcare and medical aesthetics sectors, and

      4/21/25 9:45:17 AM ET
      $HAO
      Advertising
      Consumer Discretionary
    • Haoxi Health Technology Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

      BEIJING, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the "Company" or "HAO"), an online marketing solution provider headquartered in Beijing, China, today announced that it received a formal notification from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company's Class A ordinary shares, par value US$0.0025 each (the "Ordinary Shares") to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's Ordinary Shares has been at $1.00 per share or greater for the last 10 consecutive business d

      2/11/25 8:30:00 AM ET
      $HAO
      Advertising
      Consumer Discretionary
    • Haoxi Health Technology Limited Announces 1-for-25 Reverse Share Split

      BEIJING, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the "Company" or "HAO"), an online marketing solution provider headquartered in Beijing, China, today announced that it has resolved to effect a reverse share split of the Company's ordinary shares, with the split ratio set at 1-for-25 (the "Reverse Share Split"). The Reverse Share Split was approved by the Company's shareholders at an annual general meeting of shareholders held on January 10, 2025. The Company's Class A ordinary shares will begin trading on an adjusted basis on the Nasdaq Capital Market, reflecting the Reverse Share Split, when the market opens on January 27, 2025, under the existing ticker symbol

      1/23/25 8:30:00 AM ET
      $HAO
      Advertising
      Consumer Discretionary

    $HAO
    Leadership Updates

    Live Leadership Updates

    See more
    • Haoxi Health Technology Limited Facilitates International Humanitarian Aid Efforts Amid Global Challenges

      Haoxi Health Technology Limited (the "Company" or "HAO"), an online marketing solution provider headquartered in Beijing, China, today announced that against the backdrop of increasing global challenges, the Company is mobilizing its resources to actively fulfill its corporate social responsibility and is closely monitoring international humanitarian needs and collaborating with relevant organizations and groups to provide essential support for international medical aid. Amidst evolving global dynamics, numerous regions face pressing humanitarian needs. The Company, renowned for its expertise in digital marketing and commitment to social responsibility, is leveraging its capabilities to a

      6/9/24 8:00:00 PM ET
      $HAO
      Advertising
      Consumer Discretionary